Pictet Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pictet Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.8M	Sell	395,382 -798,279	-67%	-$43.7M	0.02%	508
2026 Q1	$67.1M	Sell	1,193,661 -89,961	-7%	-$5.25M	0.07%	267
2025 Q4	$76.4M	Buy	1,283,622 +393,409	+44%	+$21.4M	0.07%	255
2025 Q3	$48.2M	Sell	890,213 -203,165	-19%	-$11.6M	0.05%	333
2025 Q2	$60.1M	Buy	1,093,378 +808,078	+283%	+$47.6M	0.06%	293
2025 Q1	$20.3M	Buy	285,300 +600	+0.2%	+$40.4K	0.02%	492
2024 Q4	$18.7M	Sell	284,700 -634,916	-69%	-$42.5M	0.02%	522
2024 Q3	$64.7M	Sell	919,616 -743,547	-45%	-$62.2M	0.07%	253
2024 Q2	$137M	Sell	1,663,163 -242,446	-13%	-$20.2M	0.16%	159
2024 Q1	$167M	Buy	1,905,609 +468,886	+33%	+$42M	0.18%	147
2023 Q4	$139M	Sell	1,436,723 -505,522	-26%	-$44.7M	0.15%	168
2023 Q3	$172M	Buy	+1,942,245	New	+$173M	0.21%	131

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Pictet Asset Management's BMRN Position: Q2 2026 in Review

Pictet Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 67% in Q2 2026, selling an estimated $43.7M and leaving 395,382 shares worth $22.8M. The position accounts for 0.02% of the portfolio, ranked #508.

Pictet Asset Management first reported a position in BMRN in Q3 2023 and has held it in 12 quarters since. The position peaked at $172M in Q3 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Pictet Asset Management held 395,382 shares of BioMarin Pharmaceuticals worth $22.8M as of Q2 2026.
Pictet Asset Management sold 798,279 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $43.7M.
BioMarin Pharmaceuticals made up 0.02% of Pictet Asset Management's portfolio in Q2 2026, its #508 holding.
Pictet Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Pictet Asset Management's BioMarin Pharmaceuticals position peaked at $172M in Q3 2023.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.